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Abstract 
Background: During the erythrocytic stage in humans, malaria parasites digest haemoglobin of the host cell, and 
the toxic haem moiety crystallizes into haemozoin. Chloroquine acts by forming toxic complexes with haem mol-
ecules and interfering with their crystallization. In chloroquine-resistant strains, the drug is excluded from the site of 
action, which causes the parasites to accumulate less chloroquine in their acid food vacuoles than chloroquine-sen-
sitive parasites. 3-Hydroxylpyridin-4-ones are known to chelate iron; hydroxypyridone-chloroquine (HPO-CQ) hybrids 
were synthesized in order to determine whether they can inhibit parasites proliferation in the parasitic digestive 
vacuole by withholding iron from plasmodial parasite metabolic pathway.
Methods: Two HPO-CQ hybrids were tested against Plasmodium falciparum chloroquine-sensitive (D10 and 3D7) and 
-resistant strains (Dd2 and K1). The pharmacokinetic properties of active compounds were determined using a mouse 
model and blood samples were collected at different time intervals and analysed using LC–MS/MS. For in vivo efficacy 
the mice were infected with Plasmodium berghei in a 4-day Peters’ test. The parasitaemia was determined from day 3 
and the course of the infection was followed by microscopic examination of stained blood films every 2–3 days until a 
rise in parasitaemia was observed in all test subjects.
Results: IC50 values of the two compounds for sensitive and resistant strains were 0.064 and 0.047 µM (compound 
1), 0.041 and 0.122 µM (compound 2) and 0.505 and 0.463 µM (compound 1), 0.089 and 0.076 µM (compound 2), 
respectively. Pharmacokinetic evaluation of these compounds showed low oral bioavailability and this affected in vivo 
efficacy when compounds were dosed orally. However, when dosed intravenously compound 1 showed a clearance 
rate of 28 ml/min/kg, an apparent volume of distribution of 20 l/kg and a half-life of 4.3 h. A reduction in parasitaemia 
was observed when compound 1 was dosed intravenously for four consecutive days in P. berghei-infected mice. How-
ever, a rise in parasitaemia levels was observed on day 6 and on day 9 for chloroquine-treated mice.
Conclusion: The hybrid compounds that were tested were able to reduce parasitaemia levels in P. berghei-infected 
mice when dosed intravenously, but parasites recrudesced 24 h after the administration of the least dose. Despite low 
oral bioavailability, the IV data obtained suggests that further structural modifications may lead to the identification of 
more HPO-CQ hybrids with improved pharmacokinetic properties and in vivo efficacy.
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Background
Malaria is a disease caused by an eukaryote parasite of 
the genus Plasmodium and remains a major global public 
health problem, that was responsible for 584,000 deaths 
in 2013, with most occurring in Africa and most deaths 
in children under 5 years of age [1, 2]. Plasmodium fal-
ciparum and Plasmodium vivax, are responsible for 
most cases of malaria and the control of these parasites 
by chloroquine and other known anti-malarial drugs has 
been compromised by the emergence and spread of drug 
resistance in many parts of the world, primarily in P. fal-
ciparum strains [3, 4]. This has severely limited the use 
of many effective anti-malarials, and has become a major 
threat to malaria elimination efforts, causing increased 
morbidity and mortality and a financial burden due to 
sustenance of replacement therapy [3].
When the parasite infects the erythrocyte, it uses the 
endolysosomal system to digest the haemoglobin in an 
acidic food vacuole, producing an oxidized form of haem, 
ferriprotoporphyrin IX (FP-IX), which is the iron con-
taining non-protein component of haemoglobin, as a by-
product [5–7]. Free FP-IX is toxic and can lyse the cell 
and affect the function of lysozomal enzymes. The para-
site disposes the toxic FP-IX by a polymerization process 
that crystallizes at least 95 % of FP-IX as haemozoin, and 
this allows an uninterrupted growth and proliferation 
of the parasite [8–10]. Iron chelators have been studied 
as alternative malaria drugs for many years because of 
their ability to interact with available iron in the nucleus 
and parasite cytosol, thereby interfering with the iron-
dependent metabolism of malaria parasites and inhibit-
ing their development [11, 12].
Hydroxypyridones are iron-chelating agents known 
to suppress malaria growth in  vivo and in  vitro [13, 
14]. Both hydroxypyridones and chloroquine target 
the erythrocytic stage of the malaria life cycle, which is 
highly dependent on iron. For the purpose of this study, 
N-alkyl-3-hydroxypyridin-4-ones were combined with 
chloroquine in an attempt to enhance antiplasmodial 
effect against chloroquine-resistant strains of P. falcipa-
rum when compared to inhibition by chloroquine alone 
[13]. Compound 1 and 2 were selected among a series of 
hydroxypyridone-chloroquine (HPO-CQ) hybrid com-
pounds in order to assess their antiplasmodial activity 
in vitro and efficacy in vivo and to evaluate their pharma-
cokinetic properties.
Methods
In vitro antiplasmodial activity 
against chloroquine‑sensitive and resistant strains
The human parasite P. falciparum strains used in this 
study were chloroquine-sensitive (CQS) (3D7 and D10) 
and chloroquine-resistant (CQR) (Dd2 and K1) and were 
obtained from the malaria reagent depository, Malaria 
Research and Reference Reagent Resource Center (MR4) 
(ATCC, Manassas, VA, USA). The parasites were con-
tinuously cultured in  vitro according to the method 
described by Trager and Jensen but with modifications 
[15]. The cultures were maintained at 37 °C in O-positive 
(O+) human erythrocytes in complete culture medium, 
which contained RPMI 1640 (Gibco-BRL Laboratories) 
growth medium supplemented with 25 mM 4-(2-hydrox-
yethyl)piperazine-1-ethanesulfonic acid (HEPES) (Sigma-
Aldrich Chemical Company) buffer, 22  mM glucose 
(Sigma), 5 g/l albumax (Gibco-BRL Laboratories), 25 mM 
sodium carbonate (Sigma) and 0.3  mM hypoxanthine 
(Sigma). In order to control microbial contamination 
50  µg/l gentamicin (Sigma) was added to the culture 
medium, and to obtain a loosely synchronous ring stage, 
5  % sterile aqueous d-sorbitol (Sigma) was used. The 
antiplasmodial assay was initiated with the parasites in 
the trophozoite stage and with a parasitaemia and haem-
atocrit of 2 %.
The test compounds were tested at a concentration 
range of 0.15–150  mM and chloroquine (Sigma) was 
tested at a concentration range of 0.003–3 and 0.0003–
0.3 mM for resistant strain and sensitive strains, respec-
tively. Non-parasitized erythrocytes were used as a 
negative control and parasitized erythrocytes, without 
any test compound, were used as positive control. A full 
day dose–response was performed for all compounds to 
determine the concentration inhibiting 50  % of parasite 
growth (IC50 value). The plates were incubated for 48  h 
at 37 °C in a gassing chamber containing a mixture of 5 % 
CO2, 3 % O2 and 92 % N3. In order to quantify parasite 
viability and to determine the effect of the compounds 
on the parasite, a parasite lactate dehydrogenase (pLDH) 
assay was used as described by Makler et al. [16, 17], but 
with modifications.
Pharmacokinetic studies
A comprehensive pharmacokinetic (PK) study of com-
pound 1 and 2 was performed on 10-week old male and 
female C57BL/6 mice (20–30 g) obtained from the Uni-
versity of Cape Town Medical School Animal Unit. The 
mice were housed in ventilated cages at room tempera-
ture (approximately 22  °C) with constant supply of food 
and water and were monitored twice daily. The study 
was authorized by the Faculty of Health Science Animal 
Research Ethics Committee before commencement: Ref-
erence No. 012/020. All the work was performed accord-
ing to the guidelines established by Austin et al. [18].
The compounds were prepared in oil-in-water (o/w) 
microemulsions, which consist of 5  % ethyl linoleate 
(Sigma), 11  % Tween 80 (Sigma), 4  % ethanol (Merck), 
and 80  % water. In each experiment a group of five 
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animals were dosed orally (10  ml/kg) at 20  mg/kg and 
intravenously (5 ml/kg) via the dorsal penile vein at 4 mg/
kg under anaesthesia. For oral dosage, a gavage nee-
dle was used for the administration of test compounds 
directly into the lower oesophagus or stomach. Blood 
samples (approximately 30 µl) were collected serially by 
needle prick on the tail vein, near to the tip of the tail, 
at 0, 0.17, 0.5, 1, 2, 3, 5, 7, and 9 h post-dosing. Lithium 
heparin-coated MiniCollect® Plasma Tubes (Lasec, 
South Africa) were used to collect the blood samples. The 
collected blood samples were placed on ice immediately 
after sampling, and were frozen at −80 °C until analysis.
Sample preparation
The blood samples stored at −80 °C were thawed at room 
temperature and then mixed by vortex to ensure homo-
geneity. Twenty µl of blood was mixed with 50 µl Milli-Q 
water (Millipore, USA) and 150  µl acetonitrile (Merck). 
The mixture was vortexed for 15 s, sonicated for 10 min 
and centrifuged at 13,000g for 5  min. The supernatant 
was transferred to a flat-bottomed glass insert and placed 
in a glass vial and placed in the autosampler for analysis.
Liquid chromatography–mass spectrometry summary
A liquid chromatography–mass spectrometry (LC/MS/
MS) system was employed for the quantification of the 
compounds in mouse blood. The LC system employed 
was an ultra-fast liquid chromatography (UFLC) system 
(Shimadzu) and the separation of the compounds was 
performed on a Phenomenex, Luna 5 μm PFP (2), 100 Å, 
50 mm × 2 mm analytical column. The mobile phase A 
consisted of 0.1 % formic acid in water (v/v) and mobile 
phase B consisted of acetonitrile. The flow rate was set at 
500 µl/min and the temperature of the column was main-
tained at 40 °C. For the separation of the compounds, the 
mobile phase was increased from 5 to 95 % B over 4 min, 
after that, phase B was returned to 5  % within 0.1  min, 
then equilibrated for 3 min.
The detection of the compounds was performed on 
an AB Sciex 3200 Q-Trap mass spectrometer which 
was operated at unit resolution in the multiple reaction 
monitoring (MRM) mode. The calibration range for all 
the compounds was between 7.8 and 1000 ng/ml and the 
accuracy (% Nom) for the calibration curves was between 
90.3 and 104.0  %. Table  1 gives an overview of the MS 
parameters and the instrument settings.
Pharmacokinetic analysis
Non-compartmental analysis was performed on each 
individual set of data using PK Solutions 2.0 Pharma-
cokinetic Analysis Software (Summit Research Services, 
Montrose, USA). The following PK parameters were 
calculated: apparent terminal half-life [t½ (min)], total 
exposure [AUC0–α (µM min)], volume of distribution (l/
kg) and plasma clearance [CL (l/min/kg)].
In vivo anti‑malarial efficacy of compound 1 against a 
chloroquine‑sensitive Plasmodium berghei strain
The chloroquine-sensitive Plasmodium berghei (ANKA 
strain) was used to assess in vivo anti-malarial efficacy of 
the test compounds. The parasites were maintained in a 
C57BL/6 mouse by inoculation with 250 µl of a 1:1 (v/v) 
suspension of erythrocytes infected with P. berghei in 
phosphate buffered saline (PBS). On the day of the exper-
iment the host mouse was anaesthetized intraperitoneally 
with a mixture of ketamine (120  mg/kg) and xylazine 
(16  mg/kg). Whole blood from the host mouse was 
drawn by cardiac puncture into a Vacuette® heparin tube 
and a suspension of P. berghei parasitized erythrocytes 
(1  ×  107) in PBS was prepared and the test mice were 
infected with 200 µl of this suspension intraperitoneally.
Evaluation of the curative potential of the test com-
pounds was performed using Peters’ 4-day test as 
described [19]. The mice were dosed orally at 20 and 
40 mg/kg and intravenously at 4 and 8 mg/kg 2 h post-
infection and for three consecutive days (D0 to D3). On 
the first day (D0), blood samples were collected serially 
from each mouse at 0.5, 1, 3, and 7 h post-dosing in order 
to provide quantitative measurements of drug exposure 
which is needed for the sound interpretation of the effi-
cacy of the anti-malarials [20]. Chloroquine was used as 
a reference drug and was dosed orally at 10 mg/kg. The 
mice were also dosed orally with PBS as a control. The 
parasitaemia was determined from the third day (D4) by 
preparing thin blood films from the tail of each mouse 
Table 1 Mass spectrometer settings and  MS parameters 
used for  the detection of  the test compounds on  an API 
3200 Q-Trap
Parameter Compound 1 Compound 2
Q1 mass (Da) 531.2 490.2
Q3 mass (Da) 91.1 261.2
Dwell time (ms) 40 40
Declustering potential (V) 91 61
Collision energy (V) 89 73
Entrance potential (V) 10 10
Collision cell exit potential (V) 4 2
Source temperature (°C) 500 500
Curtain gas (psi) 25 25
Gas 1 (psi) 50 50
Gas 2 (psi) 70 70
CAD gas Medium Medium
Ion spray voltage (kV) 5500 5500
Ionization mode Positive Positive
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and the smears were fixed with methanol and stained 
with Giemsa. This was repeated every 2–3 days to moni-
tor the efficacy of the test compounds. The formula used 
to calculate % parasitaemia and % reduction is described 
below, respectively. The data for % parasitaemia and % 
reduction of parasitaemia is presented in Table 4.
 
Results
Antiplasmodial action of the compounds in vitro
Compounds 1 and 2 were synthesized in order to 
enhance the activity of chloroquine by combining it with 
an iron chelator. These compounds were tested for anti-
plasmodial activity against sensitive strains 3D7 and D10 
and resistant strains K1 and Dd2 and the IC50 values (in 
µM) of compounds 1 and 2 are summarized in Table 2. 
The P values were calculated using the non-parametric 
Mann–Whitney U test in order to compare the activity 
of chloroquine with that of the HPO-CQ hybrids. The 
resistance index (RI), the ratio of the IC50  of the resist-
ant strain to that of the sensitive strain, was calculated 
for these compounds using the lowest IC50 value of the 
sensitive and the highest IC50 of the resistant strain for 
each compound, which should give the highest RI value 
for that compound [21]. This value provides a quantita-
tive measurement of the antiplasmodial activity against 
CQR strains relative to that against CQS strains [22]. The 
higher the RI value, the higher the level of resistance. The 
RI value was calculated according to this formula [23]:
% Parasitaemia
=
No. of parasitized RBC out of 500 erythrocytes
Total no. of RBC counted
× 100
% Reduction
=
Parasitamia of placebo − Parasitamia of test compound
Parasitamia of placebo
× 100
Resistance Index (RI) =
Chloroquine− resistant strain IC50
Chloroquine− sensitive strain IC50
The IC50 values calculated from the dose response 
curves were in the range of 0.041–0.064 µM against 3D7 
and 0.047–0.122  µM against D10. These values were 
higher than that of chloroquine, with IC50 values of 0.019 
and 0.023  µM against 3D7 and D10, respectively. The 
IC50 values of the compounds against the resistant strain 
K1 and Dd2 were compared to those of chloroquine (IC50 
values of 0.279 and 0.180  µM for K1 and Dd2, respec-
tively). Compound 2 was more active than chloroquine 
with IC50 values of 0.089 and 0.076 µM for K1 and Dd2, 
respectively. Compound 1 on the other hand was less 
active than chloroquine with IC50 values of 0.505 and 
0.463  µM for K1 and Dd2, respectively. The data pre-
sented in Table 2 show that the difference in the activity 
of the HPO-CQ hybrids when compared to chloroquine 
is insignificant at P  >  0.05 in all chloroquine-sensitive 
strains. However, activity of the two compounds against 
the resistant strains differed significantly. The compounds 
had lower RI values than chloroquine. Compound 2 had 
an RI value of 2.2, which is over five times less than that 
of chloroquine and the RI value of compound 1 was 10.7 
(Fig. 1).
Pharmacokinetics
The compounds were administered to mice orally and 
intravenously at 20 and 4 mg/kg, respectively. The blood 
levels for both compounds in the mice dosed orally could 
not be detected because the values were below the limit 
of quantitation (LOQ). The concentration versus time 
intravenously (IV) profiles of both compounds is pre-
sented in Fig. 2. The mean concentration–time data were 
used to calculate the PK parameters by non-compart-
mental analysis using PK Solutions 2.0 Pharmacokinetic 
Analysis Software. The PK parameters are presented in 
Table 3.
Compound 1 showed a clearance rate of 28 ml/min/kg, 
a high apparent volume of distribution of 20  l/kg and a 
half-life of 4.3 h. The area under the curve (AUC) value 
was also at 196 µM min. Even with the half-life of 4.3 h, 
the compound remained at detectable levels of 0.16 µM 
Table 2 In vitro IC50 values (µM) of compounds 1 and 2
The values obtained from antiplasmodial tests represent the mean of three independent experiments each performed in triplicate
RI value, values calculated using the highest CQR IC50 value and lowest CQS IC50 value; n/a, not applicable
Test compounds Sensitive strains Resistant strains RI P value
3D7 D10 K1 Dd2
1 0.064 ± 0.02 0.047 ± 0.01 0.505 ± 0.10 0.463 ± 0.12 10.7 0.343
2 0.041 ± 0.02 0.122 ± 0.03 0.089 ± 0.01 0.076 ± 0.01 2.2 1
Chloroquine 0.019 ± 0.00 0.023 ± 0.00 0.279 ± 0.002 0.180 ± 0.01 14.4 n/a
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after 9  h at the end of the dosing interval, indicating a 
slow elimination rate from circulation. When consider-
ing these properties and IC50 values of 0.064–0.505  µM 
against sensitive and resistant strains, respectively, com-
pound 1 was selected for in  vivo efficacy studies. Even 
though the compound could not be detected in blood fol-
lowing an oral dosage, investigating the efficacy of com-
pound 1 after an intravenous dosage was considered.
Compound 2, on the other hand, had a very short half 
life of 0.7  h and after 2  h the blood levels dropped to 
0.03 µM because of a high clearance rate of 366 ml/min/
kg. The volume of distribution was also high at 154.1 l/kg.
Anti‑malarial effect of compound 1 on Plasmodium 
berghei‑infected mice
The PK evaluation shows that compound 1 and 2 lev-
els were below the LOQ. They both presented poor PK 
properties following oral administration. However, the 
LC–MS/MS assay only detected the parent compound 
and no assays were conducted to measure or identify any 
possible metabolites. The decision to perform efficacy 
studies was based on the possibility that compounds 1 
and 2 may have high first pass effect which may cause low 
bioavailability. After the infected mice were dosed orally 
and intravenously with compound 1 and 2, the blood 
concentrations were measured in P. berghei-infected mice 
at different time intervals to measure the exposure of 
the infected mice to the drug. The blood concentration 
levels of the mice that were dosed orally were below the 
Fig. 1 The structures of synthesized hydroxypyridone-chloroquine hybrids (compound 1 and 2)
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Fig. 2 Blood concentrations of compounds 1 (a) and 2 (b) in C57BL/6 mice blood after intravenous administration of 4 mg/kg. Data represent 
mean ± standard deviation of data points obtained from five single mice
Table 3 Pharmacokinetic parameters of hydroxypyridone-
chloroquine hybrids after intravenous administration
Data represent mean ± standard deviation of data points obtained from five 
uninfected mice
ND indicate that the value was not determined
Parameters Compound 1 Compound 2
T1/2 (h) 4.3 ± 1.02 0.7 ± 0.2
Vss (l/kg) 20.1 ± 6 154.1 ± 1
CL (ml/min/kg) 27.6 ± 8 366 ± 46.6
AUC0–∞ (µM min) 196 ± 29.9 25.2 ± 3.4
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detection level in both 20 and 40 mg/kg groups. Figure 3 
shows concentration versus time profiles of compound 
1 following IV administration in mice infected with P. 
berghei. For compound 2 the IV data showed a very high 
clearance rate compared to compound 1 and blood con-
centration levels were very low. High toxicity was also 
detected when dosed orally and intravenously. The PK 
studies were only conducted for 9  h, and therefore the 
symptoms of toxicity were not severe. However, with effi-
cacy studies the mice are dosed every day for 4 days, and 
this might cause distress to the mice because the toxic 
effect of the drug will be more severe. The efficacy study 
for compound 2 is not reported in this paper.
When considering compound 1 blood concentration 
of healthy animals in Fig.  2a and P. berghei-infected 
animals in Fig.  3, it was noted that higher drug lev-
els were observed in infected mice. It is unlikely that 
the presence of parasites could be the reason for such 
a significant difference in blood levels because the 
mouse exposure study was performed 2  h post infec-
tion and parasitized erythrocytes are rapidly absorbed 
after intraperitoneal inoculation [24]. This differ-
ence could possibly be due to the variation in age and 
weight.
To evaluate the anti-malarial efficacy of compound 1 
in infected mice, the parasitaemia level was calculated at 
days 4, 6 and 9 post infection, and the % reduction of par-
asitaemia was calculated for day 9 only because parasite 
levels were observed in all treated mice on day 9.
In the mice that were dosed orally, the parasites were 
visible at a parasitaemia of ±5  % on day 4. These data 
correlate well with the PK data because the blood levels 
of compound 1 following oral dosage were too low to 
have any effect on reducing parasitaemia, and thus allow-
ing the disease to progress as indicated by a rise in the 
parasitaemia levels, as shown in Table 4. It was also noted 
that the parasitaemia in mice that were dosed orally was 
higher than the parasitaemia in the placebo group. This 
may mean that high oral doses may cause compound 1 to 
be immunosuppressive, thus allowing the infection to be 
severe in the oral group when compared to the placebo 
group. High parasitemia levels in the 40 mg/kg/day oral 
group resulted in a negative value of % reduction of para-
sitaemia (Table 4).
As expected, blood levels remained high for a longer 
period for mice dosed intravenously with 4 and 8  mg/
kg of compound 1 as shown in the concentration ver-
sus time profiles in Fig. 3. These data are consistent with 
the comprehensive PK study presented in Table 3, which 
shows that compound 1 had a half-life of 4.3 h following 
intravenous dosage and a clearance rate of 28 ml/min/kg. 
Figure 3 shows that after 7 h following intravenous dos-
age the blood concentration levels were relatively high for 
4 and 8 mg/kg. This resulted in a reduced parasite mul-
tiplication rate as indicated by undetected to low parasi-
taemia until day 4 and 6. However, the data suggest that 
compound 1 suppressed the parasitaemia without clear-
ing all parasites, therefore, surviving parasites in the mice 
blood began to multiply after the 4-day course of treat-
ment, causing a parasite reduction to decrease to 62 
and 83 % in the mice dosed at 4 and 8 mg/kg on day 9, 
0
0.5
1
1.5
2
2.5
0 2 4 6 8
[C
om
po
un
d 
1]
 
M
Time (hours)
IV @ 4mg/kg
IV @ 8mg/kg
Fig. 3 Blood levels of compound 1 in C57BL/6 mice blood infected 
with P. berghei after intravenous administration of 4 and 8 mg/kg of 
compound. Data represent mean ± standard deviation of data points 
obtained from five mice
Table 4 In vivo antiplasmodial efficacy of compounds 1 in C57BL/6 mice blood infected with P. berghei
Data represent mean ± standard data points obtained from five mice
Test group Average % parasitemia % reduction  
of parasitemia
Day 4 Day 6 Day 9 Day 9
Oral (20 mg/kg/day) 5.3 ± 3.9 22.7 ± 10 24.2 ± 5.6 3.7 ± 5.6
Oral (40 mg/kg/day) 5.9 ± 2 10.7 ± 5 48.6 ± 12 −93.8 ± 49.3
IV (4 mg/kg/day) 0.4 ± 0.4 1.8 ± 1.4 8.1 ± 5 61.9 ± 26
IV (8 mg/kg/day) 0 0.9 ± 0.9 5.1 ± 1.7 82.9 ± 2.5
Oral CQ (10 mg/kg/day) 0 0 2 ± 1.6 92.0 ± 0.4
Placebo 2.5 ± 2.4 7.3 ± 2.4 25.1 ± 0.4 –
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respectively, as shown in Table 4. This also shows that the 
efficacy of compound 1 is dose dependent.
Conclusion
The aim of synthesizing HPO-CQ hybrids was to develop 
anti-malarial candidates that were potent against sensi-
tive and resistant P. falciparum strains. This study showed 
that combining chloroquine with a HPO can cause a 
change in the physicochemical properties of the hybrid, 
thus affecting its efficacy and PK properties. Chloroquine 
alone has an oral bioavailability of 79–90 % and a half-life 
of 7 h in mice, as reported by Salako [25]. Even though 
compound 2 was more active than chloroquine in  vitro 
against the resistant strains with a lower RI value, the PK 
properties were not improved relative to chloroquine. 
Compound 1 was less active in  vitro against the resist-
ant strains than compound 2 and chloroquine with poor 
oral bioavailability, but it proved to be an effective anti-
malarial compound in  vivo when dosed intravenously. 
Nevertheless, chloroquine remained more effective 
in vivo than both compounds and this means that further 
modifications on the chemical structure could improve 
PK properties, such as oral bioavailability, thus improving 
efficacy.
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